SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

this coin is scarce

SCARCE CRYPTO is trending as social media buzz points to a potential breakout, with community members noting its "coiled" chart pattern and "understated strength." The coin, associated with the Solana ecosystem, is being watched for a major move as participants speculate about whale accumulation and a possible surge.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

StarkNet ($STRK) is trending as community members highlight its potential for a significant breakout, fueled by renewed accumulation and a reclaim of key support levels. Discussions revolve around StarkNet's integration with Zcash ($ZEC) to bring privacy and scalability to Layer 2, with many seeing it as a bullish development. Increased developer activity and protocol upgrades further contribute to the positive sentiment.

To honor the incredible bravery of Daboo, a heartfelt movement has been created to keep his memory alive The initiative celebrates Daboo's unwavering loyalty and courage while promoting causes that align with his heroic spirit, such aS animal rescue efforts, shelter funding, and pet safety awareness Through storytelling, Daboo's legacy serves as a reminder of the selfless love that animals offer to humans. By sharing his story and supporting these meaningful causes, the memory of Daboo continues to inspire kindness and compassion, ensuring his heroic act is never forgotten No Rug Pulls, No Get Rich Scams. Just Pure love for the meme coins!

Daboo

DABOO is trending as the community discusses its potential and recent price action, with some users highlighting its small supply and AI aspects. There's also discussion around potential connections to other cryptocurrencies like BTC, SOL and ETH, as well as comparison to other tokens. However, some users are also expressing concerns about bots and potential scam activity.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as its community rallies around a shared vision, emphasizing their strong belief in the project's long-term success, particularly within the Solana ecosystem. Active community members are encouraging each other to stay focused and united, aiming to outperform other projects. The community's enthusiasm is palpable, with members expressing readiness for upcoming developments.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community buzzes around potential catalysts and upcoming integrations like ZAP. Some users highlight the coin's strong community and potential for growth within the Bitcoin ecosystem, with many expressing a bullish outlook.

Aris Mining Corp. engages in the provision of gold mining services. It operates through the Segovia, Soto Norte, Toroparu, Juby and Marmato mines in Colombia. The company was founded in 1982 and is headquartered in Vancouver, Canada.

Aris Mining Corp

Aris Mining Corporation

Aris Mining ($ARMN) is gaining attention as a junior gold miner with significant upside, particularly due to its projects in South America. Community discussions revolve around its attractive valuation, organic growth potential, and comparisons to larger mining companies. Recent news includes positive developments from the Soto Norte project and increased ownership, contributing to the stock's trending status.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

DASH is trending as community members discuss its potential to follow ZEC's recent surge, emphasizing DASH's limited supply and increased interest in privacy coins. The community is anticipating a breakout past key resistance levels, with some speculating on factors that could contribute to a significant rally. Bullish sentiment is building around DASH's potential for growth.

zkSync

ZK Crypto (zkSync) is trending as the community discusses its potential for growth and recent news around partnerships and technological advancements. Some are pointing to upcoming token unlocks as a potential headwind, while others highlight integrations and real-world asset tokenization efforts as bullish catalysts. Community members are actively debating entry points and long-term price targets, with some expressing excitement about its role in Ethereum scaling.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the crypto market experiences volatility, sparking debates about potential bottom prices and future growth. Community sentiment is mixed, with some seeing buying opportunities amidst the dips, while others express concerns about market manipulation and the prevalence of meme coins on the Solana blockchain. The overall discussion revolves around whether Solana can maintain its position against other cryptos like Ethereum and Bitcoin.

Airbnb, Inc. engages in the management and operation of an online marketplace. Its marketplace model connects hosts and guests online or through mobile devices to book spaces. The company was founded by Brian Chesky, Nathan Blecharczyk and Joseph Gebbia in 2007 and is headquartered in San Francisco, CA.

Airbnb Inc - Ordinary Shares - Class A

Airbnb Inc

Airbnb is trending as the community discusses potential integration with Instacart and debates the company's valuation amidst fluctuating market conditions. Some analysts are adjusting price targets, while others express concerns about growth and competition, particularly with hotels; discussion around new offerings such as hotels on the platform have been debated.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials ChemDiv Extends CMC Services Collaboration for...

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. Dover...

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move that removes a key policy tailwind for vaccine developers, including Moderna, Novavax, CureVac, and Traws Pharma.The CDC reportedly deactivated its response last week and will now track bird flu alongside seasonal influenza, updating human monitoring data monthly, Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-07/bird-flu-emergency-response-ends-in-us-as-infections-decline">reported</a>.&nbsp;Animal transmission data will no longer be published, the agency said. Washington and California, two of the most affected states, have also scaled back efforts.&nbsp;California ended its emergency declaration in April, while Washington is downsizing its public health response. The U.S. Department of Health and Human Services stated that the CDC’s transition reflects a return to regular program operations.&nbsp;During the response, 375 CDC staff had been assigned to the outbreak, the agency added.The CDC’s move comes amid broader federal cutbacks. Earlier this year, HHS scrapped a $766 million deal with Moderna for developing mRNA bird flu vaccines.Public health officials said a decline in surveillance would make it harder to spot the next outbreak.&nbsp; “We are letting our guard down,” said Michael Kinch, an infectious disease expert at Stony Brook University.In January, heightened bird flu fears had boosted attention on pandemic-preparedness companies.&nbsp;The U.S. reported its first human death from H5N1 in Louisiana and awarded $306 million for avian flu response, including $176 million to&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> for its mRNA-1018 vaccine candidate.<a href="https://stocktwits.com/symbol/NVAX">Novavax</a> had been advancing pre-clinical H5N1 vaccine research, while Germany’s&nbsp;<a href="https://stocktwits.com/symbol/CVAC">CureVac</a> partnered with&nbsp;<a href="https://stocktwits.com/symbol/GSK">GlaxoSmithKline</a> on another bird flu shot.&nbsp;Traws Pharma, which is developing a one-dose antiviral therapy called tivoxavir marboxil, disclosed promising preclinical results in December 2024 and plans a Phase 2 trial this year.Bird flu has infected at least 70 people in the U.S. since the start of the outbreak, mostly agricultural workers. While most cases have been mild, one fatality was recorded in January. The virus remains a concern in migratory birds and cattle.Retail sentiment on Stocktwits was mixed across vaccine makers: ‘bullish’ for Moderna and GSK, ‘neutral’ for Novavax, and ‘bearish’ for CureVac. Meanwhile, message volume was ‘high’ for GSK, ‘normal’ for Moderna and Novavax, and ‘extremely low’ for CureVac.Year to date, Moderna shares are down 28.8%, Novavax has fallen 22.9%, while CureVac has gained 56.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Equity

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu Traws Pharma Announces...

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program PR Newswire SAN DIEGO, Jan...

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval Traws Pharma, Inc...

Traws Pharma shares surged more than 200% on Monday, reaching highs seen in June after the company announced significant progress in developing its investigational one-dose influenza therapy, tivoxavir marboxil, for H5N1 bird flu treatment.&nbsp;Trading volume skyrocketed to over 2,600 times the daily average.In laboratory studies, tivoxavir marboxil demonstrated efficacy against highly pathogenic H5N1 influenza isolates.&nbsp;Traws’ Chief Science Officer David Pauza highlighted preclinical results, showing complete survival and reduced lung virus levels in mice infected with human H5N1 isolated from a dairy worker exposed to infected cattle.&nbsp;CEO Werner Cautreels added that Phase 1 clinical trial data confirmed the therapy’s safety and tolerability.&nbsp;A Phase 2 study is planned for the first half of 2025, the company said.The announcement comes amid escalating concerns over H5N1’s&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.nbcnews.com/health/health-news/bird-flu-cases-spread-warning-signs-rcna185084">spread</a>.&nbsp;The U.S. has reported 64 infections since April, with dairy herds in 16 states affected.&nbsp;Last week, California declared a state of emergency after an uptick in cases among dairy cows, and Louisiana reported the country’s first severe human infection.Retail interest&nbsp;in Traws surged on Monday, making its stock one of the top three trending symbols on Stocktwits.&nbsp;Discussions on the platform were mixed, with some predicting a breakout above $20 — a level last seen in April — and others cautioning about a potential share offering due to the company’s tight financial position.&nbsp;<stembedurl>https://stocktwits.com/miraclehunter/message/597607177</stembedurl><stembedurl>https://stocktwits.com/MarketAce/message/597606552</stembedurl>As of the last quarter, Traws had $5.4 million in cash and $11 million in liabilities, according to data on Koyfin.In addition to tivoxavir marboxil, Traws Pharma’s pipeline includes ratutrelvir for COVID-19, targeting viral proteases, and investigational cancer therapies like narazaciclib and rigosertib, which focus on cell cycle proteins.Traws Pharma began trading on&nbsp;the Nasdaq in April following the acquisition of Trawsfynydd Therapeutics by Onconova Therapeutics.&nbsp;Still, the stock remains down 24% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of chickens and a rooster at a farm as California declares a state of emergency to prevent a new public health crisis on Bird flu in Pescadero, California, United States on December 20, 2024. (Photo by Tayfun Coskun/Anadolu via Getty Images)

Traws Pharma Stock Hits 6-Month Highs On Bird Flu Treatment Breakthrough, Retail Interest Soars

The U.S. has reported H5N1 Bird Flu 64 infections since April, with dairy herds in 16 states affected. 

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu PR Newswire NEWTOWN, Pa., Dec...

Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment

Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir...

Earnings Scheduled For April 16, 2024

Companies Reporting Before The Bell
 Traws Pharma (NASDAQ:TRAW) is expected to report earnings for its fourth quarter.
read more...

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Traws Pharma Inc.

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

TRAW
Traws Pharma Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRAW News

TRAWTraws Pharma Inc.